Wechalekar, A. D., Dispenzieri, A., Sanchorawala, V., Kastritis, E., Bhutani, D., Bianchi, G., Jimenez-Zepeda, V. H., Suzuki, K., Lentzsch, S., Huart, A., Carpinteiro, A., Swenson, E. S., Khan, Z., Catini, J., Kulkarni, H., Meltzer, B. A., Mercuri, M., Lake, S., Liedtke, M. (2026). Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7501